Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Claire Andrews, Taylor Young, Eshetu G Atenafu, M.Sc., P.Stat, Sarit E Assouline, MD MSc, Joseph M Brandwein, MD, Steven M Chan, MD PhD, Signy Chow, MD FRCP(C), Dina Khalaf, BSc, MSc, MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Dawn Maze, MDFRCPC,MSc, Mark D. Minden, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, David Sanford, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Karen W.L. Yee, MD, Hassan Sibai, MBBS

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142990

Published: 2020

Journal Articles

Bendamustine Adversely Affects Stem Cell Mobilization Among Patients with Mantle Cell Lymphoma (MCL): A Comparison of the BR Vs RCHOP Eras in British Columbia (BC), Canada

Hatem Alahwal, MPH, MBBS, Parv Chapani, Diego Villa, MD FRCPC, Yasser Abou Mourad, MD, Maryse Power, MD, Stephen H. Nantel, MD, David Sanford, MD, Gayatri Sreenivasan, BSc, MD, Heather J. Sutherland, MD PhD, Laurie H Sehn, MD MPH, Cynthia L. Toze, MD FRCPC, MSc, Raewyn Broady, MBChB, Kevin Song, MD, Paul Yenson, MD BSc, FRCPC, Alina S. Gerrie, MD MPH

Blood (2018) 132 (Supplement 1): 4556.

https://doi.org/10.1182/blood-2018-99-114371

Published: 2018

Journal Articles

Older Adults with Acute Myeloid Leukemia in Rural Areas Are Less Likely to Receive Azacitidine with Worsened Overall Survival

Ryan J Stubbins, MD MSc, Lauren Lee, MD, Yasser Abou Mourad, MD, Michael J Barnett, BM, Raewyn Broady, MBChB, Donna L. Forrest, MD, Alina S. Gerrie, MD MPH, Donna E. Hogge, MD PhD, Stephen H. Nantel, MD, Sujaatha Narayanan, MBBS, Thomas J Nevill, MD, Maryse Power, MD, Kevin Song, MD, Heather J. Sutherland, MD PhD, Cynthia L Toze, MD, Jennifer White, MD, David Sanford, MD

Blood (2018) 132 (Supplement 1): 3989.

https://doi.org/10.1182/blood-2018-99-111532

Published: 2018

Journal Articles

Unsuccessful Cytogenetics and Outcomes in Acute Leukemia

Lauren Lee, MD, Helene Bruyere, MD, Michael J Barnett, BM, Raewyn Broady, MBChB, Donna L. Forrest, MD, Alina S. Gerrie, MD MPH, Donna E. Hogge, MD PhD, Stephen H. Nantel, MD, Sujaatha Narayanan, MBBS, Maryse Power, MD, David Sanford, MD, Kevin Song, MD, Heather J. Sutherland, MD PhD, Cynthia L Toze, MD, Jennifer White, MD, Yasser Abou Mourad, MD

Blood (2018) 132 (Supplement 1): 2673.

https://doi.org/10.1182/blood-2018-99-110470

Published: 2018

Journal Articles

Characteristics of Patients (pts) Who Relapse and Die of Multiple Myeloma (MM) within One Year Post Frontline Autologous Stem Cell Transplant (ASCT) in the Novel Agent Era: An Ultra-High Risk Population

Hatem Alahwal, MPH, MBBS, Heather J. Sutherland, MD PhD, Shruthi Ganeshappa Kodad, MD, Stephen H. Nantel, MD, Yasser Abou Mourad, MD, Michael J. Barnett, BMBS, Donna L. Forrest, MD, Alina S. Gerrie, MD MPH, Donna E. Hogge, MD PhD, Sujaatha Narayanan, MBBS, MRCP, MRCPath, Thomas J. Nevill, MD, Maryse Power, MD, David Sanford, MD, Cynthia L. Toze, MD FRCPC, MSc, Jennifer White, MD, Raewyn Broady, MBChB, Kevin Song, MD

Blood (2018) 132 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2018-99-111533

Published: 2018

Journal Articles

Provincial Disparities in Access to Allogeneic Transplant in Canada

Kristjan Paulson, MD, Oliver Bucher, Geoffrey Cuvelier, MD, Andrew Daly, MD, Alina S. Gerrie, MD MPH, David Sanford, MD, David Szwajcer, MD FRCP(C), Matthew Seftel, MRCP, MD MPH, FRCPC, Irwin Walker, MBBS, Natasha Kekre, MD FRCPC, Tony H Truong, MD FRCPC, Donna Wall, MD CCPE, Kirk R. Schultz, MD, Stephen Couban, MDBSc, Christopher Bredeson, MD FRCPC, MSc

Blood (2018) 132 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2018-99-113849

Published: 2018

Journal Articles

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Erica Tsang, Diego Villa, MD, Federica Loscocco, Alina S Gerrie, MD, Giuseppe Visani, Maryse Power, MB, Barbara Guiducci, Cristina Clissa, MD PhD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc, Kevin W Song, MD, Cindy Toze, Yasser Abou-Mourad, Heather Sutherland, MD, David Sanford, MD, Stephen H Nantel, MD, Laurie H. Sehn, MDMPH, David W. Scott, MD PhD FRACP, FRCPA, Alessandro Isidori, MD PhD

Blood (2017) 130 (Supplement 1): 3291.

https://doi.org/10.1182/blood.V130.Suppl_1.3291.3291

Published: 2017

Journal Articles

Prognosis and Application of Day 14 Bone Marrow Results in Acute Myeloid Leukemia Induction

James England, MD, Lalit Saini, MD, Donna Hogge, Artur J Szkotak, MD PhD, Joseph M. Brandwein, MD FRCPC, Monika Hudoba, MD, Nadejda Medvedev, MD, Tyler Smith, MD, Roland Kristine, MD, David Sanford, MD

Blood (2017) 130 (Supplement 1): 3917.

https://doi.org/10.1182/blood.V130.Suppl_1.3917.3917

Published: 2017

Journal Articles

Outcomes of Intermediate Risk Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared to Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-Score Adjusted Analysis

Wasithep Limvorapitak, MD, Michael J Barnett, BM, Donna Hogge, Donna L Forrest, MD, Thomas J Nevill, MD, Sujaatha Narayanan, MBBS, Maryse Power, MB, Stephen H Nantel, MD, Raewyn Broady, MBChB, FRACP, Kevin W Song, MD, Cynthia L Toze, MD, Yasser Abou Mourad, MD, Heather Sutherland, MD, Alina S Gerrie, MD, Jennifer White, MD, David Sanford, MD

Blood (2017) 130 (Supplement 1): 4544.

https://doi.org/10.1182/blood.V130.Suppl_1.4544.4544

Published: 2017

Journal Articles

Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics

Daniel Sawler, MD BSc, David Sanford, MD, Joseph M. Brandwein, MD FRCPC, Irwindeep Sandhu, MDFRCPC, Donna Hogge, Lalit Saini, MD

Blood (2017) 130 (Supplement 1): 464.

https://doi.org/10.1182/blood.V130.Suppl_1.464.464

Published: 2017

Journal Articles

Response Kinetics and Factors Predicting Survival Among Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Prajwal Boddu, MD, Christopher Gurguis, MS, Jorge E. Cortes, MD, Mary Akosile, Farhad Ravandi, MBBS, David Sanford, MD, Mark Brandt, BS, Rita Maduike, Tapan Kadia, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2017) 130 (Supplement 1): 27.

https://doi.org/10.1182/blood.V130.Suppl_1.27.27

Published: 2017

Journal Articles

Long-Term Outcomes of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Etoposide and Cyclophosphamide

Amir Siddiqui, Donna E. Hogge, MD PhD, Thomas J. Nevill, MD, Stephen H. Nantel, MD FRCPC, Michael J Barnett, BMBS, Raewyn Broady, MBChB, Donna L. Forrest, MD, Sujaatha Narayanan, MBBS, MRCP, FRCPath, Maryse M Power, MD, Kevin W. Song, MD, Cynthia L. Toze, MD MHSc, FRCPC, Yasser Abou Mourad, MD, Heather J. Sutherland, MD PhD, Alina S. Gerrie, MD MPH, FRCPC, David Sanford, MD FRCPC

Blood (2016) 128 (22): 2814.

https://doi.org/10.1182/blood.V128.22.2814.2814

Published: 2016

Journal Articles

Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada

Katie Y. Zhu, BHSc, Kevin W. Song, MD, Joseph M Connors, MD, Tracy Tucker, PhD FCCMG, Graham W. Slack, MD, Yasser Abou Mourad, MD, Michael J Barnett, BMBS, FRCPC, FRCP, FRCPath, Donna L. Forrest, MD FRCPC, Donna E. Hogge, MD PhD, Stephen H. Nantel, MD FRCPC, Sujaatha Narayanan, MBBS, MRCP, FRCPath, Thomas J. Nevill, MD FRCPC, Maryse M Power, MB, MRCPI, FRCPath, David Sanford, MD FRCPC, Cynthia L. Toze, MD MHSc, FRCPC, Heather J. Sutherland, MD PhD FRCPC, Laurie H. Sehn, Raewyn Broady, MBChB, FRACP, Alina S. Gerrie, MD MPH, FRCPC

Blood (2016) 128 (22): 1113.

https://doi.org/10.1182/blood.V128.22.1113.1113

Published: 2016

Journal Articles

Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia

Blood (2016) 128 (22): 5852.

https://doi.org/10.1182/blood.V128.22.5852.5852

Published: 2016

Journal Articles

Improving Revised International Prognostic Scoring System (IPSS-R) Pre-Allogeneic Stem Cell Transplant Does Not Translate into Better Post-Transplant Outcomes for Patients with Myelodysplastic Syndromes

Musa Alzahrani, MBBS, ABIM, Maryse M Power, MD, Emilie Nevill, Yasser Abou Mourad, MD, Michael J Barnett, BMBS, Raewyn Broady, MBChB, Donna L. Forrest, MD, Alina S. Gerrie, MD MPH, FRCPC, Donna E. Hogge, MD PhD, Stephen H. Nantel, MD FRCPC, David Sanford, MD FRCPC, Heather J. Sutherland, MD PhD FRCPC, Cynthia L. Toze, MD MHSc, FRCPC, Kevin W. Song, MD, Kevin W. Song, MD, Thomas J. Nevill, MD FRCPC, Sujaatha Narayanan

Blood (2016) 128 (22): 4662.

https://doi.org/10.1182/blood.V128.22.4662.4662

Published: 2016

Journal Articles

Prognostic Impact of Kinase Mutations and Minimal Residual Disease in Core-Binding Factor Leukemia

David Sanford, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Wei Qiao, Keyur P. Patel, MD PhD, Thuyvan Hoang, Tapan Kadia, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2015) 126 (23): 3828.

https://doi.org/10.1182/blood.V126.23.3828.3828

Published: 2015

Journal Articles

Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses

David Sanford, MD, Francesco LoCoco, MD, Miguel A. Sanz, MD PhD, Eros Di Bona, MD, Steven Coutre, MD, Jessica K. Altman, MD, Meir Wetzler, MD, Steven L. Allen, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 3751.

https://doi.org/10.1182/blood.V124.21.3751.3751

Published: 2014

Journal Articles

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Rachel MA Kyle, BSc, Alejandro Lazo-Langner, MD, MSc, Anargyros Xenocostas, MD, FRCPC, Ian H. Chin-Yee, MD, FRCPC, Kang Howson-Jan, MD, David Sanford, MD, Cyrus C. Hsia, BSc, MD, FRCPC

Blood (2012) 120 (21): 4274.

https://doi.org/10.1182/blood.V120.21.4274.4274

Published: 2012

NARROW

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Bendamustine Adversely Affects Stem Cell Mobilization Among Patients with Mantle Cell Lymphoma (MCL): A Comparison of the BR Vs RCHOP Eras in British Columbia (BC), Canada

Older Adults with Acute Myeloid Leukemia in Rural Areas Are Less Likely to Receive Azacitidine with Worsened Overall Survival

Unsuccessful Cytogenetics and Outcomes in Acute Leukemia

Characteristics of Patients (pts) Who Relapse and Die of Multiple Myeloma (MM) within One Year Post Frontline Autologous Stem Cell Transplant (ASCT) in the Novel Agent Era: An Ultra-High Risk Population

Provincial Disparities in Access to Allogeneic Transplant in Canada

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Prognosis and Application of Day 14 Bone Marrow Results in Acute Myeloid Leukemia Induction

Outcomes of Intermediate Risk Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared to Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-Score Adjusted Analysis

Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics

Response Kinetics and Factors Predicting Survival Among Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Long-Term Outcomes of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Etoposide and Cyclophosphamide

Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada

Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia

Improving Revised International Prognostic Scoring System (IPSS-R) Pre-Allogeneic Stem Cell Transplant Does Not Translate into Better Post-Transplant Outcomes for Patients with Myelodysplastic Syndromes

Prognostic Impact of Kinase Mutations and Minimal Residual Disease in Core-Binding Factor Leukemia

Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only